OVERVIEW

International Inflammatory Breast Cancer is organized by The University of Texas MD Anderson Cancer Center and will be held on Dec 05, 2020.

Accreditation:
Physicians:
The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live internet course for a maximum of 4.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Goal:
Inflammatory breast cancer (IBC) is a highly aggressive breast cancer, with a very poor prognosis relative to other breast cancers due to its strong potential to metastasize, relapse, and possibly result in patient death. There have been multiple attempts to develop efficacious targeted therapy for this disease. Unfortunately, the federal government (FDA) has not approved any IBC-specific drugs or diagnostic tools yet. Therefore, there remains an urgent need to understand mechanistically how to induce a therapeutic effect that can prolong the survival of patients with IBC. This two-day meeting is targeted for clinical investigators, practicing physicians, basic researchers, patient advocates and institutions aiming to pioneer IBC clinics in their geographic regions, to enhance their knowledge and to facilitate collaboration to accelerate clinical therapy and research trial development, beneficial for patients with IBC. They expect new ideas and collaborations from this meeting to lead to improvement of disease outcome, such as survival or tumor response, over the next 3 years.

Educational Objectives:
• Review IBC and metastatic breast cancer standard of care diagnosis and treatment including the rationale for differences from other breast cancers;
• Discuss ongoing clinical trials of IBC and metastatic breast cancer from both the biology perspective and operations to discuss expansion of collaboration in the US;
• Incorporate new concepts in the biology and latest developments of the ongoing translational research related to IBC and metastatic breast cancer;
• Discuss how they can translate our basic research findings as clinical research or into the clinic.